Mon. May 25th, 2026
Spread the love

McKinsey & Company’s Consumer practice and the Mckinsey Institute for Black Economic Mobility have joined forces with the New Voices Foundation (New Voices) to accelerate the growth of Black-owned brands. Through this collaboration, McKinsey & Company (McKinsey) will provide strategic support to New Voices member businesses (known affectionately as the New Voices Family) via its Next 1B: Scalers program and work directly with the New Voices team to expand and fine tune its operations, capacity and impact.
“Despite increasing demand from consumers and retailers, Black-owned brands face outsized challenges to profitable scaling. And we know that improving the success rate of Black-owned businesses is an essential component of improving economic mobility for communities,” says Tiffany Burns, McKinsey Senior Partner. “We believe, together with New Voices, we can change the odds by working hand-in-hand with these entrepreneurs to create bold and achievable growth plans.”
The Next 1B program is being rolled out to five New Voices Family businesses this year. Each brand works with a dedicated McKinsey team to understand the full opportunity across marketing, sales, product and operations, sequence growth levers and build a roadmap. They also receive guidance on pressing, near-in business questions, such as pricing, digital media or talent strategy.
This effort builds on the longstanding commitments that both McKinsey and New Voices Foundation have made. McKinsey’s 10 Actions for Racial Equity includes a commitment of $200M in pro bono work to advance racial equity and doubling spending with diverse suppliers. At New Voices, this builds on the impact already achieved within their network of 30,000+ Black and women of color entrepreneurs, which New Voices has supported through 1,300+ hours of business education, mentoring and coaching, significant networking opportunities, $25M+ of new capital to entrepreneurs.
“We are excited to work with McKinsey to expand the New Voices Foundation’s impact on people of color and woman-owned businesses,” says New Voices Foundation Chair, Richelyna Hall. “McKinsey brings its considerable expertise on scaling businesses profitably, and have demonstrated their commitment to small and minority-owned businesses.”
This collaboration comes alongside the 1-year anniversary of McKinsey’s Next 1B program launch. Over the past 12 months, Next 1B has worked with over 100 Black-owned businesses in its 2-month-long capability-building program, Founders, and has led growth projects for several businesses through the Scalers program.
“The Next 1B Scaler program has helped us create more equitable opportunities for our business. We are grateful for this collaboration; it provides best-in-class resources that add real value to founders. The work has helped us validate strategy, quantify assumptions and create insights that are actionable.” – Jason Crain, President, Slutty Vegan, Inc.

By admin

You missed

From Tramadol to Canadian to Exol-5 The New Drug Destroying Nigerian Youths An Investigative Article .From Tramadol to Canadian to Exol-5: The New Drug Destroying Nigerian Youths An Investigative Report on the Shifting Landscape of Substance Abuse in Nigeria Nigeria faces a severe and evolving drug crisis, particularly among its youth. What began with the widespread abuse of Tramadol has progressed through mixtures like “Canadian” to newer pharmaceutical diversions such as Exol-5. This shift reflects deeper issues: easy access to prescription drugs, weak regulation, socioeconomic pressures, and aggressive street-level marketing. NDLEA operations and health studies reveal a public health emergency that threatens an entire generation. Phase 1: The Tramadol Epidemic (2010s–Early 2020s) Tramadol, a synthetic opioid prescribed for moderate to severe pain, became Nigeria’s most notorious street drug. Cheap, potent, and widely smuggled (often from India and other Asian countries), it offered users energy, euphoria, and pain relief — appealing to commercial drivers, laborers, students, and young men seeking confidence or stamina. Scale of the Problem: Millions of tablets seized annually by NDLEA. High prevalence among young males aged 15–35. Linked to increased crime, sexual violence, organ damage (kidney failure, seizures), and mental health breakdowns. Contributed to broader opioid misuse alongside codeine cough syrups. Government responses included tighter import controls and public awareness campaigns, but these only displaced demand to other substances rather than eliminating it. Phase 2: The Rise of “Canadian” (Mid-2020s) “Canadian” or “Canadian Loud” emerged as a popular code for high-grade cannabis (often indica-dominant strains) or cannabis mixed with other synthetics. It gained traction as users sought alternatives or combinations to Tramadol’s effects. This phase marked a move toward imported or locally cultivated premium weed, sometimes laced with stronger chemicals. Youths in urban centers like Lagos, Kano, Jos, and Onitsha embraced it for its perceived “cleaner” high compared to opioids. However, it fueled polydrug use — combining cannabis with opioids, sedatives, or alcohol — amplifying health risks. Phase 3: Exol-5 – The Current Threat (2024–2026) Exol-5 (Benzhexol Hydrochloride / Trihexyphenidyl 5mg), originally a prescription medication for Parkinson’s disease and drug-induced movement disorders, has become the latest pharmaceutical being heavily abused. Why Exol-5? Euphoric Effects: Users report intense euphoria, hallucinations, and a sense of detachment — making it attractive as a cheap “upper” or escape. Accessibility: Sold over-the-counter or on the black market despite being a controlled prescription drug. NDLEA has seized millions of pills in single operations (e.g., 3.1 million pills in Kano in late 2024, and over 5.6 million combined with Tramadol in other busts). Street Names: Exol, Artane, Benzhexol, “Farin Mallam” (in Northern Nigeria). Demographics: Prevalent among youths, laborers, and even psychiatric patients who divert prescriptions. Studies show abuse rates as high as 25% among certain outpatient groups. Health Consequences: Anticholinergic toxicity: Confusion, dry mouth, blurred vision, urinary retention, constipation, and in high doses — delirium, psychosis, seizures, and heart issues. Long-term: Cognitive impairment, addiction, exacerbated mental health disorders. Often mixed with Tramadol, codeine, or cannabis, creating dangerous synergies. In cities like Jos, Exol-5 sits alongside diazepam, Rohypnol, and Tramadol on street markets, easily available to teenagers and young adults. Why This Evolution Continues Supply-Side Failures: Porous borders, corrupt officials, and overproduction of pharmaceuticals enable diversion. Demand Drivers: Unemployment, poverty, peer pressure, trauma, and the pursuit of performance enhancement (e.g., for “hustle” culture). Weak Regulation: Many pharmacies sell restricted drugs without prescriptions. Online and street vendors fill gaps. Displacement Effect: Cracking down on one substance (Tramadol/codeine) pushes users and dealers toward the next available option. NDLEA reports ongoing large seizures, but the problem persists due to high profitability and low risk for mid-level distributors. Broader Impacts on Nigerian Youths Education: Increased dropout rates and poor academic performance. Mental Health: Rising cases of psychosis and depression. Economy: Lost productivity among the working-age population. Crime and Violence: Drug-fueled robberies, cultism, and family breakdowns. Public Health System Strain: Overburdened hospitals treating overdoses and chronic complications. Young people aged 15–39 remain the hardest hit, with national surveys showing drug use prevalence significantly above global averages. What Must Be Done Stronger Enforcement: Consistent prosecution of corrupt enablers and large-scale traffickers. Regulation: Crackdown on rogue pharmacies and better tracking of prescription drugs. Prevention & Rehabilitation: School programs, community outreach, and expanded treatment centers (currently woefully inadequate). Economic Alternatives: Address root causes like youth unemployment. Public Awareness: Honest campaigns highlighting real dangers of “Exol-5” and similar drugs. Conclusion From Tramadol’s opioid grip to “Canadian” cannabis culture and now Exol-5’s anticholinergic highs, Nigeria’s drug crisis is mutating faster than responses can contain it. Exol-5 represents the dangerous new frontier — a legitimate medicine turned youth destroyer due to misuse and greed. Without urgent, multi-layered intervention — combining supply disruption, demand reduction, and socioeconomic support — an entire generation risks being lost to addiction. The time for half-measures is over. Nigeria’s future depends on winning this fight.